HUTCHMED closes exclusive global license with GSK for KRAS‑EGFR antibody‑drug conjugate
HUTCHMED Limited completed a licensing agreement with a GSK subsidiary that gives GSK worldwide rights, except for Mainland China, Hong Kong, Macau and Taiwan, to develop and commercialize the KRAS‑EGFR antibody‑drug conjugate HMPL‑A830. The deal provides HUTCHMED with an upfront cash payment of $110 million and the possibility of further milestone payments that could total up to $1.185 billion. HUTCHMED will run the Phase I portion of the global trial, while GSK will take over all later development and marketing activities in its territories.
Why it matters
The upfront cash bolsters HUTCHMED’s balance sheet and the potential milestones could add significant future revenue if development milestones are met, according to the company’s statement. GSK gains a novel oncology asset for markets outside China, expanding its pipeline in KRAS‑altered cancers.
Key facts
- 1The agreement was closed on Oct. 20, 2026 after satisfying customary closing conditions, including antitrust regulatory reviews. marketscreener.com
- 2GSK receives worldwide rights to HMPL‑A830, excluding Mainland China, Hong Kong, Macau and Taiwan. marketscreener.com
- 3HUTCHMED will receive a $110 million upfront payment shortly after closing. marketscreener.com
- 4Additional milestone payments, covering development, regulatory and commercial achievements, could total up to $1.185 billion. marketscreener.com
- 5HUTCHMED will conduct the global Phase I development program, while GSK will handle all subsequent clinical development and commercialization. marketscreener.com
- 6The Phase Ia portion of a global trial for HMPL‑A830 began in September 2026 in China and the United States. marketscreener.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.